Diligence memo · auto-generated · as of July 2, 2026
Sage Therapeutics, Inc.
Sage Therapeutics, Inc. has raised $698M over 3 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Sage Therapeutics, Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sage Therapeutics, Inc. has raised $698M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $650M on 2020-12-31.
Most recent recorded round closed around 2020-12-31.
Valuation (modeled)modeled
Provath models Sage Therapeutics, Inc. at approximately $20.7B (range $4.3B–$35.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 42 months.
Last raise 5.5 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 17.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Catalent, Inc., Lyell Immunopharma, Inc..
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.